GlassScriptPhysician profile
Genevieve H Hinks
NPI 1982086013
$4,820.74
in general payments reported to CMS, 2019-2025
27 companies · $306 in 2025
The $306 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $413 · 2020: $149 · 2021: $3,371 · 2022: $253 · 2023: $131 · 2024: $197 · 2025: $306.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $634.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $633.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $3,433.45 | 2021-2022 | |
| Hologic Sales and Service, LLC | $194.73 | 2020-2025 | Aptima |
| Lsi Solutions INC | $123.40 | 2019 | |
| Asensus Surgical, INC. | $120.83 | 2019 | |
| Organon LLC | $119.82 | 2022-2025 | Nexplanon |
| Abbvie INC. | $117.09 | 2019-2024 | |
| Sage Therapeutics, LLC | $97.26 | 2019 | |
| Sumitomo Pharma America, INC. | $82.92 | 2023-2025 | Myfembree |
| Astrazeneca Pharmaceuticals LP | $51.52 | 2024-2025 | Airsupra |
| Merck Sharp & Dohme LLC | $51.29 | 2024-2025 | Gardasil 9, Gardasil, Capvaxive |
| Millicent US INC | $43.32 | 2025 | Intrarosa, Femlyv, Femring |
| Shield Therapeutics INC | $39.29 | 2025 | |
| Pfizer INC. | $36.91 | 2020-2024 | |
| Astellas Pharma US INC | $36.59 | 2023-2025 | Veozah |
| Exact Sciences Corporation | $33.21 | 2024 | Cologuard Collection Kit |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Channel Medsystems, INC. | $32.99 | 2025 | |
| Myovant Sciences INC. | $29.87 | 2022 | |
| Axonics, INC. | $24.80 | 2023 | Axonics |
| Exeltis, USA INC. | $23.26 | 2024 | Slynd |
| Biohaven Pharmaceutical Holding Company LTD. | $21.84 | 2022 | |
| Baxter Healthcare | $17.62 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $17.12 | 2025 | |
| Urovant Sciences INC | $16.05 | 2022 | |
| Therapeuticsmd, INC. | $15.61 | 2022 | |
| Novo Nordisk INC | $14.84 | 2023 | Wegovy |
| Mycovia Pharmaceuticals, INC. | $13.46 | 2023 | Vivjoa |
| Bausch Health US, LLC | $11.65 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Genevieve Hinks listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.